CATALYST PHARMACEUTICALS INC (CPRX) Stock Analyst Ratings
USA - NASDAQ:CPRX - US14888U1016 - Common Stock
22.78 USD
-0.32 (-1.39%)
22.78 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 89% to CPRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 34.68. This target is 52.24% above the current price.
CPRX was analyzed by 14 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about CPRX.
In the previous month the buy percentage consensus was at a similar level.
CPRX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-02-04 | Baird | Initiate | Outperform |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-09 | B of A Securities | Reiterate | Buy -> Buy |
| 2024-11-18 | Stephens & Co. | Initiate | Overweight |
| 2024-11-11 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-09 | Citigroup | Maintains | Buy -> Buy |
| 2024-06-06 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Citigroup | Initiate | Buy |
| 2024-03-07 | B of A Securities | Initiate | Buy |
| 2024-03-01 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-21 | Oppenheimer | Initiate | Outperform |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-21 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-21 | Truist Securities | Maintains | Buy |
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the average price target for CATALYST PHARMACEUTICALS INC (CPRX) stock?
14 analysts have analysed CPRX and the average price target is 34.68 USD. This implies a price increase of 52.24% is expected in the next year compared to the current price of 22.78.
What is the consensus rating for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The consensus rating for CATALYST PHARMACEUTICALS INC (CPRX) is 88.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for CATALYST PHARMACEUTICALS INC stock?
The number of analysts covering CATALYST PHARMACEUTICALS INC (CPRX) is 14.